Clinical trials: Upper Urinary Tract Urothelial Carcinoma
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Urothelial carcinoma is the most common cancer of the urinary system. It includes bladder cancer and upper urinary tract cancer, which starts in the kidney pelvis or ureter.
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT07888374
- Where
- China
- Volunteers
- 477 people
- Sponsor
- Ruijin Hospital
Bladder Cancer, Urothelial Carcinoma
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06040762
- Testing
- Best Practice, Exercise Intervention, App-Based Intervention
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Washington
Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO [mitomycin] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of…
- Trial name
- NCT06774131
- Testing
- UGN-104
- Where
- 79 sites in United States, Bulgaria and 7 more
- Volunteers
- 70 people
- Sponsor
- UroGen Pharma Ltd.
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
This is a two-stage, prospective, single-center observational diagnostic accuracy study evaluating noninvasive urine testing for the detection of urothelial carcinoma (UC).
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
- Trial name
- NCT07614594
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Henan Provincial People's Hospital
Bladder Cancer, Urothelial Carcinoma (UC)
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
- Trial name
- INSITE (NCT07673016)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 2,500 people
- Sponsor
- Convergent Genomics, Inc.
Upper Urinary Tract Urothelial Carcinoma, Nephroureterectomy
New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.
Upper Urinary Tract Urothelial Carcinomas are rare, aggressive tumors, accounting for 5 to 10% of all urothelial tumors. These include tumors which develop in the renal cavities (renal pelvis, calices) and ureteral tumors.
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Nephroureterectomy, Tumor, Xenograft Model
- Trial name
- CICLOP (NCT04944550)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Upper Urinary Tract Urothelial Carcinoma
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC
This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU)…
- Trial name
- HERO-UTUC (NCT07591805)
- Testing
- Drug: Disitamab Vedotin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- RenJi Hospital
Urinary Bladder Cancer, Upper Tract Urothelial Cancer
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of…
- Conditions
- Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
- Trial name
- NCT06822010
- Testing
- Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rutgers, The State University of New Jersey
Neoadjuvant Therapy, Urothelial Carcinoma Ureter
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
This clinical trial aims to compare the effectiveness and safety of two treatment options for patients with high-risk upper tract urothelial carcinoma (UTUC).
- Conditions
- Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
- Trial name
- NCT07492225
- Testing
- Neoadjuvant Gemcitabine + Cisplatin Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changhai Hospital
Bladder Cancer, Urothelial Carcinoma
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- DUET-UC-NK (NCT07492628)
- Testing
- EB-DT-NK-UC101, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Upper Urinary Tract Urothelial Carcinoma
The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract
This is a study looking at how patients with a rare type of cancer in the pelvis and ureter of the kidney - called upper urinary tract urothelial carcinoma (UTUC) - is currently treated.
- Trial name
- EuroCUT (NCT07077447)
- Testing
- Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma
- Where
- 5 sites in Denmark, Norway
- Volunteers
- 2,500 people
- Sponsor
- Zealand University Hospital
Upper Urinary Tract Urothelial Carcinoma
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
In this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II…
- Trial name
- NCT06210490
- Testing
- Disitamab Vedotin, Radiotherapy, Standard of Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg…
- Conditions
- Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney
- Trial name
- NCT06354231
- Testing
- DV, Toripalimab, Laser surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies.
- Trial name
- NCT04672330
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- RenJi Hospital
Upper Urinary Tract Urothelial Carcinoma
Translational Cancer Observational Protocol
Observational study on relapse occurrence and on the quality of life in patients who underwent nephroureterectomy surgery
- Trial name
- NCT06169436
- Testing
- Nephroureterectomy
- Where
- Italy
- Volunteers
- 1,250 people
- Sponsor
- IRCCS San Raffaele
Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer
Single-Dose Intravesical Chemotherapy After Diagnostic URS
Study design This study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy of a single immediate intravesical chemotherapy instillation (SI) in the prophylaxis of intravesical recurrence…
- Trial name
- MINERVA (NCT05810623)
- Testing
- Intravesical Solution
- Where
- 2 sites in Austria
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- David D'Andrea
Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive biomarkers of immunotherapy.
- Trial name
- NCT05160285
- Testing
- Nivolumab 100 MG in 10 ML Injection
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- YULISU
Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
This study is designed prospectively to investigate the safety and efficacy of neoadjuvant PD-1 monoclonal antibody combined with cisplatin-based chemotherapy in patients with locally advanced upper urinary tract urothelial…
- Trial name
- NCT04672317
- Testing
- Immunotherapy combined with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center